Pomerantz LLP is investigating a potential securities fraud lawsuit against Regeneron Pharmaceuticals following the company's announcement that its Phase 3 trial for a melanoma treatment failed to meet key endpoints. The trial results showed no significant improvement in progression-free survival compared to existing therapy, causing Regeneron's stock to fall nearly 10%. Investors are advised to contact the law firm regarding possible claims. This legal action highlights risks investors face when clinical trials do not meet expectations.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...
The European Medicines Agency (EMA) has accepted Regeneron Pharmaceuticals' Marketing Authorization Application for Otarmeni (lunsotogene parvec), a gene therapy targeting biallelic OTOF variant-associated hearing loss, for accelerated assessment. Ot...
